Dr. Ravits is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UCSD ACTRI, 9452 Medical Center Drive, Ste 2W-108
La Jolla, CA 92037Phone+1 206-909-5475Fax+1 858-657-8557
Education & Training
Clinical Center at the National Institutes of HealthResidency, Neurology, 1984 - 1986
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1983 - 1984
University of California (San Diego) Medical CenterInternship, Transitional Year, 1979 - 1980
Mayo Clinic College of MedicineClass of 1979
Certifications & Licensure
CA State Medical License 2011 - 2027
WA State Medical License 1985 - 2013
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Clinical Neurophysiology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Mexiletine for the Treatment of Muscle Cramps in ALS Start of enrollment: 2013 May 01
- A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2021 Sep 02
Roles: Principal Investigator
Publications & Presentations
PubMed
- 1 citationsCK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis.Vivian I Ko, Kailee Ong, Deborah Y Kwon, Xueying Li, Alicia Pietrasiewicz
Acta Neuropathologica Communications. 2024-12-04 - Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised,...Leonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, Suma Babu, Michael Benatar
The Lancet. Neurology. 2024-09-01 - 2 citationsCK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation.Vivian I Ko, Kailee Ong, Don W Cleveland, Haiyang Yu, John M Ravits
Neurobiology of Disease. 2024-06-15
Journal Articles
- Transcriptome–Pathology Correlation Identifies Interplay Between TDP-43 and the Expression of Its Kinase CK1E in Sporadic ALSJohn Ravits, MD, Acta Neuropathologica
Press Mentions
ALS-Causative Mutations in FUS/TLS Confer Gain- and Loss-of-Function by Altered Association with SMN and U1-snRNPJanuary 27th, 2020
Researchers Describe New ALS Biomarkers, Potential New Drug TargetsJuly 16th, 2019
Restoring Levels of Membralin Protein May Extend Survival in ALS, Mouse Study SuggestsJune 12th, 2019- Join now to see all
Grant Support
- Microgenomic Studies Of ALSNational Institute Of Neurological Disorders And Stroke2006–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
